KRAS and combined KRAS/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant therapy

BACKGROUND: The response of rectal cancers to neoadjuvant chemoradiation (CRT) is variable, but tools to predict response remain lacking. We evaluated whether KRAS and TP53 mutations are associated with pathologic complete response (pCR) and lymph node metastasis after adjusting for neoadjuvant regi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Surg Oncol
Autors principals: Chow, Oliver S., Kuk, Deborah, Keskin, Metin, Smith, J. Joshua, Camacho, Niedzica, Pelossof, Raphael, Chen, Chin-Tung, Chen, Zhenbin, Avila, Karin, Weiser, Martin R., Berger, Michael F., Patil, Sujata, Bergsland, Emily, Garcia-Aguilar, Julio
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5047012/
https://ncbi.nlm.nih.gov/pubmed/27020587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-016-5205-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars